NASDAQ: FBLGFibrobiologics Inc Stock
$1.75-0.16 (-8.38%)
Updated Jan 17, 2025
FBLG Price
$1.75
Fair Value Price
$0.26
Market Cap
$60.65M
52 Week Low
$1.08
52 Week High
$55.00
P/E
-2.92x
P/B
22.16x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.83
Operating Cash Flow
-$10M
Beta
0.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FBLG Overview
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FBLG's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
F
Momentum
B
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FBLG
Ranked#157 of 557
Ranked#157 of 557
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $20.13 | A | |
| $121.18 | A | |
| $5.94 | A |
Be the first to know about important FBLG news, forecast changes, insider trades & much more!
FBLG News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FBLG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FBLG ($1.75) is overvalued by 566.18% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
FBLG ($1.75) is not significantly undervalued (566.18%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FBLG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FBLG due diligence checks available for Premium users.
Valuation
FBLG fair value
Fair Value of FBLG stock based on Discounted Cash Flow (DCF)
Price
$1.75
Fair Value
$0.26
Overvalued by
566.18%
FBLG ($1.75) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FBLG ($1.75) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FBLG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FBLG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.92x
Industry
-135.26x
Market
30.45x
FBLG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
22.16x
Industry
4.73x
FBLG is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FBLG's financial health
Profit margin
Revenue
$0.0
Net Income
-$500.0k
Profit Margin
0%
FBLG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.5M
Liabilities
$7.7M
Debt to equity
2.83
FBLG's short-term assets ($8.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FBLG's short-term assets ($8.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FBLG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
-$11.0k
Financing
$4.5M
FBLG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FBLG vs Biotech Stocks
Fibrobiologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.